Viridian Therapeutics, Inc. (VRDN)
24.18
+0.16
(+0.67%)
USD |
NASDAQ |
Aug 25, 16:00
24.18
0.00 (0.00%)
After-Hours: 19:59
Viridian Therapeutics Gross Profit Margin (Quarterly) : 58.80% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 58.80% |
| March 31, 2026 | 14.18% |
| December 31, 2025 | -142.4% |
| September 30, 2025 | 99.56% |
| June 30, 2025 | -317.3% |
| March 31, 2025 | -340.3% |
| December 31, 2024 | -70.83% |
| September 30, 2024 | -283.7% |
| June 30, 2024 | -652.8% |
| March 31, 2024 | -379.2% |
| December 31, 2023 | -386.1% |
| September 30, 2023 | -365.3% |
| June 30, 2023 | -500.0% |
| March 31, 2023 | -109.2% |
| December 31, 2022 | 0.00% |
| September 30, 2022 | 0.00% |
| June 30, 2022 | 38.67% |
| March 31, 2022 | 35.19% |
| December 31, 2021 | -195.3% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 98.56% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 12.57% |
| September 30, 2016 | 30.98% |
| June 30, 2016 | 28.15% |
| March 31, 2016 | 23.11% |
| December 31, 2015 | 30.80% |
| September 30, 2015 | -15.17% |
| June 30, 2015 | 7.63% |
| March 31, 2015 | -17.83% |
| December 31, 2014 | -39.01% |
| September 30, 2014 | 33.01% |
| June 30, 2014 | 46.94% |
| December 31, 2013 | 36.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.66% |
| Return on Assets | -46.72% |
| Return on Invested Capital | -53.73% |
| Profit Margin (Quarterly) | -44.76K% |
| Operating Margin (Quarterly) | -44.46K% |
| Return on Net Operating Assets | -1.87K% |